Clinical Trial Update: The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/Phase 2 trials are evaluating CAR-T cell therapy for relapsed or refractory malignant hematologic tumors, including aggressive B-cell non-Hodgki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Aggressive B-cell Non-hodgkin Lymphoma
• B-cell Acute Lymphoblastic Leukemia
• Multiple Myeloma
• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoma

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia) | Phase 1, Phase 2 | Status: RECRUITING